Axogen (AXGN) director Burke receives 14,150 shares from vested RSU grant

Rhea-AI Filing Summary

Axogen, Inc. director William P. Burke reported a routine equity compensation event. On June 19, 2026, 14,150 restricted stock units vested and were delivered as 14,150 shares of common stock, reflecting an annual equity grant for his service on the Board of Directors.

Each restricted stock unit represented a right to receive one share of Axogen common stock. Following this vesting and conversion, Burke directly holds 14,250 shares of common stock. No open-market purchases or sales were reported, and there are no remaining derivative holdings from this RSU grant.

Insights

Equity compensation analyst

Routine director equity vesting with no open‑market trading signal.

Director William P. Burke had 14,150 restricted stock units vest into common shares as part of his annual equity grant valued at $150,000 on the grant date. This is standard board compensation rather than a discretionary market trade.

The filing shows no related sales, gifts, or tax-withholding dispositions, and net buy/sell shares are zero. With 14,250 shares held afterward and no remaining derivatives from this grant, the activity primarily updates his ownership record. It carries limited informational value about his view of Axogen stock.

Insider Trade Summary

14,150 shares exercised/converted

Mixed 2 txns

Insider Burke William P. Mr.

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	14,150	$0.00	--
Exercise	Common Stock	14,150	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 14,250 shares (Direct, null)

Footnotes (1)

1. This reflects the number of restricted stock units that vested June 19, 2026. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

Key Figures

RSU shares vested: 14,150 shares Common shares received: 14,150 shares Shares held after transaction: 14,250 shares +2 more

5 metrics

RSU shares vested 14,150 shares Restricted stock units vested on June 19, 2026

Common shares received 14,150 shares Shares of Axogen common stock delivered upon RSU vesting

Shares held after transaction 14,250 shares Director’s direct ownership following RSU conversion

Equity grant valuation $150,000 Annual equity grant value as of the grant date for Board service

Net buy/sell shares 0 shares Transaction summary net buy/sell direction neutral

Key Terms

Restricted Stock Units, contingent right, Annual equity grant, derivative exercise/conversion

4 terms

Restricted Stock Units financial

"This reflects the number of restricted stock units that vested June 19, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."

Annual equity grant financial

"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors."

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burke William P. Mr.

(Last) (First) (Middle)

C/O AXOGEN, INC. 13631 PROGRESS BLVD.

SUITE 400

(Street)

ALACHUA FLORIDA 32615

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/19/2026		M		14,150(1)	A	$0	14,250	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	06/19/2026		M		14,150		(3)	(3)	Common Stock	14,150	$0	0	D

Explanation of Responses:

1. This reflects the number of restricted stock units that vested June 19, 2026.

2. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

3. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

Remarks:

	/s/ Marc Began, as attorney-in-fact for William Burke	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Axogen (AXGN) director William P. Burke report in this Form 4?

He reported vesting of 14,150 restricted stock units that converted into 14,150 Axogen common shares. This reflects an annual equity grant for his Board service, not an open‑market purchase or sale, and updates his direct share ownership position.

How many Axogen (AXGN) shares does William P. Burke hold after this transaction?

After the vesting and conversion, William P. Burke directly holds 14,250 shares of Axogen common stock. This total reflects the addition of 14,150 shares delivered from vested restricted stock units under his annual equity compensation award.

Were any Axogen (AXGN) shares bought or sold on the market in this Form 4?

No open‑market purchases or sales are reported. The Form 4 shows restricted stock units vesting and converting into common shares at a stated price of zero, a typical accounting entry for equity awards rather than a discretionary market trade by the director.

What are the terms of William P. Burke’s Axogen (AXGN) restricted stock unit grant?

The annual equity grant for Board service was based on a $150,000 valuation as of the grant date and vested on June 19, 2026, one year after grant. Each restricted stock unit provided a contingent right to receive one share of Axogen common stock.

Does this Axogen (AXGN) Form 4 indicate remaining derivative or RSU holdings for Burke?

The filing shows 14,150 restricted stock units converting into common shares with zero units remaining afterward in this grant. The derivative summary is empty, indicating no remaining derivative positions are visible in this specific Form 4 for the reported transactions.